A phase 3 randomized, placebo-controlled double-blind study of ARN-509 plus abiraterone acetate (AA) in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract


Authors: Rathkopf, D. E.; Attard, G.; Efstathiou, E.; Yu, M. K.; Griffin, T. W.; Todd, M. B.; Wu, D.; Kheoh, T.; Zhao, X.; Saad, F.
Abstract Title: A phase 3 randomized, placebo-controlled double-blind study of ARN-509 plus abiraterone acetate (AA) in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)
Meeting Title: 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 33
Issue: 15 Suppl.
Meeting Dates: 2015 May 29-Jun 2
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2015-05-20
Language: English
ACCESSION: WOS:000358036904780
PROVIDER: wos
Notes: Meeting Abstract: TPS5071 -- Source: Wos
MSK Authors
  1. Dana Elizabeth Rathkopf
    144 Rathkopf